The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...